Testing the drug liso-cel as a first treatment for adults with lymphoma that starts in the brain and spinal cord
Original title: A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage trial, so the drug is still being tested in people.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This trial is testing a drug called liso-cel in adults with a lymphoma that starts in the brain and spinal cord, who cannot have a transplant.
Who this trial is for. This trial is for adults with primary central nervous system lymphoma. That is a lymphoma that starts in the brain and spinal cord. It is for people who cannot have a transplant. The trial is testing a drug called lisocabtagene maraleucel, also called liso-cel or Breyanzi, given as the first treatment.
Where it stands. There are no results yet. The trial team is looking at how safe the drug is and how well it works. Those answers are not in yet. This study has not reported results.
What this means, and what it doesn't
What it could mean: This is one place where a new treatment is being tried for this kind of lymphoma. If this sounds like your situation, you can ask your care team about it. They can tell you if a trial is worth looking into for you.
What it doesn't mean: This does not mean liso-cel is a proven treatment for this lymphoma. A trial is a test. We do not yet know if it helps. Joining a trial is not a guarantee that you will be helped, and it is not a promise of a cure. Only the trial team can decide who can join.
Source: ClinicalTrials.gov, July 29, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.